JP2020530306A5 - - Google Patents
Info
- Publication number
- JP2020530306A5 JP2020530306A5 JP2020520430A JP2020520430A JP2020530306A5 JP 2020530306 A5 JP2020530306 A5 JP 2020530306A5 JP 2020520430 A JP2020520430 A JP 2020520430A JP 2020520430 A JP2020520430 A JP 2020520430A JP 2020530306 A5 JP2020530306 A5 JP 2020530306A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- scfv domain
- quadruspecific
- binding specificity
- percentage homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024064619A JP7685095B2 (ja) | 2017-06-25 | 2024-04-12 | 多重特異性抗体とその作製及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524558P | 2017-06-25 | 2017-06-25 | |
| US62/524,558 | 2017-06-25 | ||
| PCT/US2018/039157 WO2019005640A2 (en) | 2017-06-25 | 2018-06-22 | MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064619A Division JP7685095B2 (ja) | 2017-06-25 | 2024-04-12 | 多重特異性抗体とその作製及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530306A JP2020530306A (ja) | 2020-10-22 |
| JP2020530306A5 true JP2020530306A5 (enExample) | 2022-02-07 |
| JP7474193B2 JP7474193B2 (ja) | 2024-04-24 |
Family
ID=64742656
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520430A Active JP7474193B2 (ja) | 2017-06-25 | 2018-06-22 | 多重特異性抗体とその作製及び使用方法 |
| JP2024064619A Active JP7685095B2 (ja) | 2017-06-25 | 2024-04-12 | 多重特異性抗体とその作製及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064619A Active JP7685095B2 (ja) | 2017-06-25 | 2024-04-12 | 多重特異性抗体とその作製及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200157224A1 (enExample) |
| EP (1) | EP3645048A4 (enExample) |
| JP (2) | JP7474193B2 (enExample) |
| KR (1) | KR102838340B1 (enExample) |
| CN (3) | CN117946277A (enExample) |
| AU (1) | AU2018295119B2 (enExample) |
| CA (1) | CA3068049A1 (enExample) |
| IL (1) | IL271260B1 (enExample) |
| SG (1) | SG11201912865VA (enExample) |
| WO (1) | WO2019005640A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102763369B1 (ko) * | 2017-06-25 | 2025-02-05 | 시스트이뮨, 인코포레이티드 | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 |
| US20250376531A9 (en) * | 2017-06-25 | 2025-12-11 | Systimmune, Inc. | Anti-4-1bb antibodies and methods of making and using thereof |
| JP7164596B2 (ja) * | 2017-08-28 | 2022-11-01 | システィミューン， インク． | 抗ｃｄ３抗体とその作製及び使用方法 |
| SG11202008474QA (en) * | 2018-03-27 | 2020-10-29 | Systimmune Inc | Guidance and navigation control proteins and method of making and using thereof |
| MX2022005330A (es) * | 2019-11-05 | 2022-05-26 | Regeneron Pharma | Moleculas de union multiespecificas con scfv en el extremo nterminal. |
| JP7592712B2 (ja) * | 2019-11-06 | 2024-12-02 | システィミューン， インク． | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 |
| US11976133B2 (en) * | 2020-01-31 | 2024-05-07 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| TWI908779B (zh) * | 2020-03-17 | 2025-12-21 | 美商西雅圖免疫公司 | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 |
| EP3988568A1 (en) * | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| IL308918A (en) * | 2021-06-09 | 2024-01-01 | Shanghai Epimab Biotherapeutics Co Ltd | Antibodies and bispecific binding proteins that bind OX40 and/or PD-L1 |
| TWI833244B (zh) * | 2021-06-18 | 2024-02-21 | 大陸商和鉑醫藥（上海）有限責任公司 | 一種雙抗組合及其應用 |
| US20250346681A1 (en) * | 2022-04-11 | 2025-11-13 | Astrazeneca Ab | T cell binding proteins |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| CN118667026A (zh) * | 2023-03-15 | 2024-09-20 | 三生国健药业（上海）股份有限公司 | 抗muc17*cd3*cd28三特异性抗体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112324B1 (en) * | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| CA2611814A1 (en) * | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| RU2769948C2 (ru) * | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US8178101B2 (en) * | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| BRPI0914251B1 (pt) * | 2008-06-25 | 2022-07-19 | Novartis Ag | Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição |
| PE20120540A1 (es) * | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| US9580509B2 (en) * | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| IL243311B (en) * | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| EP3083696B1 (en) * | 2013-12-20 | 2018-02-14 | F.Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| EP3107569A4 (en) * | 2014-02-20 | 2018-02-21 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| JP6666905B2 (ja) * | 2014-05-29 | 2020-03-18 | スプリング バイオサイエンス コーポレーション | Ｐｄ−ｌ１抗体及びその使用 |
| EP3174897B1 (en) * | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| WO2016105450A2 (en) * | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| EP3253790A4 (en) * | 2015-02-06 | 2018-07-25 | University of Maryland, Baltimore | Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection |
| MY193229A (en) * | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| WO2017011342A1 (en) * | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| CA2998174A1 (en) * | 2015-09-15 | 2017-03-23 | Amgen Inc. | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
| EP3356401B1 (en) * | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN106397598B (zh) * | 2016-02-23 | 2020-07-14 | 上海交通大学 | 多价多特异性抗体及免疫杂合蛋白的表达和制备方法 |
| KR102763369B1 (ko) * | 2017-06-25 | 2025-02-05 | 시스트이뮨, 인코포레이티드 | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 |
| SG11202008474QA (en) * | 2018-03-27 | 2020-10-29 | Systimmune Inc | Guidance and navigation control proteins and method of making and using thereof |
-
2018
- 2018-06-22 US US16/615,123 patent/US20200157224A1/en active Pending
- 2018-06-22 EP EP18822881.1A patent/EP3645048A4/en active Pending
- 2018-06-22 AU AU2018295119A patent/AU2018295119B2/en active Active
- 2018-06-22 CN CN202410190782.3A patent/CN117946277A/zh active Pending
- 2018-06-22 JP JP2020520430A patent/JP7474193B2/ja active Active
- 2018-06-22 CN CN201880039406.7A patent/CN110799540B/zh active Active
- 2018-06-22 SG SG11201912865VA patent/SG11201912865VA/en unknown
- 2018-06-22 CA CA3068049A patent/CA3068049A1/en active Pending
- 2018-06-22 CN CN202410191002.7A patent/CN117946278A/zh active Pending
- 2018-06-22 KR KR1020207002348A patent/KR102838340B1/ko active Active
- 2018-06-22 IL IL271260A patent/IL271260B1/en unknown
- 2018-06-22 WO PCT/US2018/039157 patent/WO2019005640A2/en not_active Ceased
-
2024
- 2024-04-12 JP JP2024064619A patent/JP7685095B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530306A5 (enExample) | ||
| JP2020530777A5 (enExample) | ||
| JP2020529864A5 (enExample) | ||
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| CN117285641A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| WO2023056312A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| JP2021501575A (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| CN117222672A (zh) | 抗cldn4-抗cd137双特异性抗体 | |
| HK40111323A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40111322A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40093821A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40088418A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40088417A (zh) | 多特异性抗体及其制备和使用方法 | |
| WO2025064498A1 (en) | Affinity-modulated anti-cd45 x pd-1 and anti-cd43 x pd-1 bispecific antibodies to treat cancer and autoimmunity | |
| NZ760913B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40097105A (zh) | 双特异性抗体及其制备和使用方法 | |
| HK40073540A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40019010A (en) | Multi-specific antibodies and methods of making and using thereof |